2017

HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice

Alison K. Esser
Washington University School of Medicine in St. Louis

Daniel A. Rauch
Washington University School of Medicine in St. Louis

Jingyu Xiang
Washington University School of Medicine in St. Louis

John C. Harding
Washington University School of Medicine in St. Louis

Michael H. Ross
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Esser, Alison K.; Rauch, Daniel A.; Xiang, Jingyu; Harding, John C.; Ross, Michael H.; Su, Xinming; Wu, Kevin; Xu, Yalin; Vij, Kiran; Ratner, Lee; Weilbaecher, Katherine N.; and et al., "HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice." Oncotarget. 8,41. 69250-69263. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6265

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Alison K. Esser, Daniel A. Rauch, Jingyu Xiang, John C. Harding, Michael H. Ross, Xinming Su, Kevin Wu, Yalin Xu, Kiran Vij, Lee Ratner, Katherine N. Weilbaecher, and et al
HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice

Alison K. Esser1,*, Daniel A. Rauch1,*, Jingyu Xiang1, John C. Harding1, Nicole A. Kohart2, Michael H. Ross1, Xinning Su1, Kevin Wu1, Devra Huey2, Yalin Xu1, Kiran Vij1, Patrick L. Green2, Thomas J. Rosol2, Stefan Niewiesk2, Lee Ratner1 and Katherine N. Weilbaecher1

1 Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA
2 Department of Veterinary Biosciences, School of Veterinary Medicine, The Ohio State University, Columbus, OH, USA
* Co-authors

Correspondence to: Katherine N. Weilbaecher, email: kweilbae@wustl.edu

Keywords: HTLV-1, ATL, leukemia, HBZ, bone

Received: June 10, 2017 Accepted: August 03, 2017 Published: August 27, 2017

ABSTRACT

Adult T-cell leukemia/lymphoma (ATL) is an aggressive T cell malignancy that occurs in HTLV-1 infected patients. Most ATL patients develop osteolytic lesions and hypercalcemia of malignancy, causing severe skeletal related complications and reduced overall survival. The HTLV-1 virus encodes 2 viral oncogenes, Tax and HBZ. Tax, a transcriptional activator, is critical to ATL development, and has been implicated in pathologic osteolysis. HBZ, HTLV-1 basic leucine zipper transcription factor, promotes tumor cell proliferation and disrupts Wnt pathway modulators; however, its role in ATL induced osteolytic bone loss is unknown. To determine if HBZ is sufficient for the development of bone loss, we established a transgenic Granzyme B HBZ (Gzmb-HBZ) mouse model. Lymphoproliferative disease including tumors, enlarged spleens and/or abnormal white cell counts developed in two-thirds of Gzmb-HBZ mice at 18 months. HBZ positive cells were detected in tumors, spleen and bone marrow. Importantly, pathologic bone loss and hypercalcemia were present at 18 months. Bone-acting factors were present in serum and RANKL, PTHrP and DKK1, key mediators of hypercalcemia and bone loss, were upregulated in Gzmb-HBZ T cells. These data demonstrate that Gzmb-HBZ mice model ATL bone disease and express factors that are current therapeutic targets for metastatic and bone resident tumors.

INTRODUCTION

Viral infections cause some of the most common malignancies worldwide including human papillomavirus (cervical cancer), hepatitis B and C viruses (liver cancer), and Epstein-Barr virus (lymphoma). The understanding of viral oncogene functions has uncovered important basic mechanisms of tumor biology that have been used to prevent and treat cancer. Human T cell Leukemia/Lymphoma Virus 1 (HTLV-1) is the only human retrovirus known to directly cause cancer [1]. Adult T cell leukemia/lymphoma (ATL) is an aggressive lymphoproliferative malignancy of T cells that develops in a subset of HTLV-1 infected patients usually after decades of clinical latency. The acute form is refractory to aggressive chemotherapy treatments and has a mean survival time of less than one year, demonstrating the need to better understand this disease [2-4].

The HTLV-1 genome contains 2 viral oncogenes, Tax and HBZ. Tax has oncogenic properties in mouse models of ATL [5, 6]. Tax is a transcription factor that acts as a co-activator for CREB binding proteins [7]. Enhanced NFAT-1, AP-1 and NF-kB pathway activation by Tax regulates lymphocyte proliferation and apoptosis [8, 9]. In addition, Tax facilitates virus transmission and increases genomic instability [10, 11]. Tax is highly immunogenic and expression is repressed in human ATL cells [12, 13]. While the oncogenic properties of Tax have been extensively investigated, HBZ was only identified as a viral oncogene within the last 15 years. HBZ is a helix-
basic loop zipper protein transcribed from the antisense strand of the HTLV-1 genome. HBZ acts as a transcription factor to negatively regulate Tax and is the only viral protein expressed in both early and late stages of human ATL [14, 15]. HBZ regulates cellular proliferation, reduces cellular aging and inhibits senescence of infected cells through enhanced expression of hTERT and JunD and inhibition of p65 and p53 [16-19]. HBZ can also impair expression of DICER and some miRNAs through removal of JunD from the DICER promoter [20]. Recent reports demonstrate that HBZ has oncogenic and inflammatory properties in animal models [21, 22].

In addition to leukemia/lymphoma, many HTLV-1 associated ATL patients develop paraneoplastic hypercalcemia and osteolytic bone lesions, which commonly occur in metastatic solid tumors such as breast and prostate, but is much less common in hematologic malignancies [23, 24]. Inhibiting bone loss in patients with bone metastases and multiple myeloma, reduced bone fracture, bone pain and improved quality of life [25]. We have previously reported that Tax transgenic mice under the Granzyme B promoter model many aspects of human ATL and that osteoclast inhibitors could inhibit the hypercalcemia and osteolytic bone lesions in these mice [5, 26, 27]. However, Tax protein is infrequently detected in primary human ATL cells, even in patients with hypercalcemia and osteolytic bone lesions. We therefore determined if HBZ, which is constitutively expressed in most human ATL cells, affects osteoclasts and bone, independent of Tax. As we did for the Tax transgenic mice, we have generated mice expressing HBZ under the Granzyme B promoter (Gzmb-HBZ) (Figure 1A). To validate targeted HBZ expression, mRNA from Gzmb-HBZ and WT mouse T cells was measured. T cells were enriched using magnetic bead isolation from whole spleen and activated by culture on CD3/CD28 coated plates for 24 hours ex vivo to increase Granzyme B and HBZ expression. Gzmb-HBZ T cells expressed HBZ mRNA by qPCR analysis (Figure 1B). HBZ was not detected in T cells from WT mice.

To determine the oncogenic potential of HBZ in this model, 4-, 12- and 18-month cohorts of WT and Gzmb-HBZ mice were evaluated for tumor development, spleen size, complete blood counts (CBCs) and white cell differentials. There was no difference in these parameters between WT and Gzmb-HBZ mice at 4- and 12-months of age (Supplementary Figure 1A-1C). However, at 18 months, 40% of Gzmb-HBZ mice developed spontaneous tumors primarily localized to mesenteric and lymphoid tissues (Figure 1A, 1C). Spleen size was increased in Gzmb-HBZ tumor bearing mice (307 ± 52 mg, n = 7) compared to non-tumor bearing Gzmb-HBZ controls (142 ± 13 mg, n = 8) (Figure 1D). White blood cell (WBC) counts were assessed in Gzmb-HBZ and WT mice. The normal range was determined as the WT mean value ± 2 standard deviations. 36% of Gzmb-HBZ mice had WBC counts outside of the normal range of 3.5 +/- 1.9 K/µl (Gzmb-HBZ WBC values of 0.8, 6.9, 8.4, 18.9 K/µl). All WT mice were within the normal range (Figure 1E). These data indicate that 66% of Gzmb-HBZ mice develop disease with overt tumors or lymphocyte abnormalities by 18 months.

Gzmb-HBZ mice develop lymphoproliferative disease that is transplantable

Tumors from Gzmb-HBZ mice were evaluated by immunohistochemistry (IHC) and flow cytometry. By IHC, Gzmb-HBZ tumors were composed of CD45+ hematopoietic cells including B220+ cells (B cells/
activated T cells) and CD3e+ cells (T cells) (Figure 2A). Flow cytometry analysis of tumors from Gzmb-HBZ mice (n = 4) was performed to evaluate T cell subpopulations. Similar to IHC, 98.5% cells were hematopoietic (CD45+). Of the CD45+ cells, 27.5% were T cells (CD3e+) and 66% were B cells (CD19+) (Figure 2B). Of the CD3e+ T cell population, 41% were CD8+ T cells and 53% were CD4+ T cells. 35% of CD4+ cells were CD25+ regulatory cells. These data demonstrate that a significant percent of cells in Gzmb-HBZ tumors were hematopoietic.

In this model, HBZ is flag-tagged and expressed in hematopoietic cells as a transgene regulated by the Granzyme B promoter. We therefore assessed HBZ expression in tumors and hematopoietic tissues including spleen and bone marrow by IHC. Expression of the flag epitope was detected in Gzmb-HBZ tumors using an anti-flag antibody (Figure 2C). Flag-HBZ positive cells were present in Gzmb-HBZ spleen and bone marrow of tibiae at 18 months. Flag-HBZ positive cells were not detected in the spleens of 4-month old mice (Supplementary Figure 1D). Two Gzmb-HBZ mice developed either a hepatic tumor or an epidermal tumor, both comprised of cells expressing cytokeratin (epithelial) but low levels of CD45. Flag-HBZ was not detected by IHC in these tumors. To confirm HBZ expression, HBZ RNA was detected by in situ hybridization. HBZ RNA was present in 12-25% of cells from Gzmb-HBZ derived tumors (Figure 2D and Supplementary Figure 1E). These data confirm that Gzmb-HBZ mice develop lymphoproliferative disease with localization of HBZ expressing cells to tumors and other hematopoietic tissues at 18 months.

A hallmark of malignant transformation is whether a transplanted tumor can proliferate in another host. Tumor cells from a primary Gzmb-HBZ mesenteric tumor (Figure 2B) or PBS were injected intravenously (iv) into NSG (n = 6) mice, which lack functional T cells, B cells, and NK cells, to look at proliferative and metastatic potential. Tumor development was assessed 2 months post tumor cell implantation. While overt tumors were not visible at 2 months, tumor cell implanted mice did develop enlarged spleens (110 ± 20 mg) compared to PBS injected controls (40 ± 2 mg) (Figure 3A). Flow cytometry analysis of splenocytes revealed a substantial difference in the percent of CD4+ and CD8+ T cells in HBZ tumor cell transplanted mice (1.6 ± 0.7, 6.3 ± 7.1, n = 3) versus PBS controls (0.36 ± 0.12, 0.12 ± 0.03, n = 3) (Figure 3B, 3C), indicating CD4 and CD8 T cells are transplantable.

We next evaluated whether Gzmb-HBZ tumor

**Figure 1: Granzyme B HBZ mice develop lymphoproliferative disease.** A. Granzyme B HBZ plasmid schematic and Gzmb-HBZ mouse. Arrow denotes a mesenchymal lymph node tumor in a Gzmb-HBZ mouse. B. HBZ mRNA expression in 4 month old WT and Gzmb-HBZ mice by Real-Time RT-PCR. C. Tumor incidence in 18-month WT and Gzmb-HBZ mice. D. Spleen weight in Gzmb-HBZ tumor free (n = 8) and tumor-bearing mice (n = 7). E. Percent of WT (n = 7) and Gzmb-HBZ (n = 15) mice with normal white blood cell counts (WBC). Normal WBC range was determined as the WT median +/- 2 standard deviations. B.-D. Statistical analysis represents mean +/- SEM. Statistical significance determined by non-parametric student’s t-test B., D. or Fisher’s exact test C., E. as appropriate. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001.
derived cells could be serially passaged in mice. Gzmb-HBZ cells derived from the primary mesenteric tumor (Figure 2B) were implanted into the peritoneal cavity of a Gzmb-HBZ mouse. At 2 months post injection, a palpable tumor was detected at the injection site (Figure 3D). The Gzmb-HBZ implanted mouse had increased

Figure 2: Lymphoid derived Gzmb-HBZ tumors express HBZ. A. Gzmb-HBZ tumor immunohistochemistry (IHC) for hematopoietic (CD45), T cells (CD3ε) and B/activated T cells (B220) in a thoracic lymph node-derived tumor. Scale bar = 50 µm. B. Flow cytometry analysis of T cell populations in a Gzmb-HBZ derived mesenteric lymph node tumor. C. Flag-HBZ expression in tumor, spleen and tibia of Gzmb-HBZ mice by IHC. Scale bar = 20 µm. D. HBZ RNA in Gzmb-HBZ tumor cells by in situ hybridization, representative images and quantification. Scale bar = 50 µm.
spleen and thymus weights compared to the PBS injected control, supporting transplant of lymphoproliferative cells (Figure 3E, 3F). To distinguish implanted tumor cells from host cells, tumor cells from the secondary tumor were implanted into NSG mice (n = 5/group). Tumor cells or WT splenocytes were injected intravenously to determine metastatic potential. At 2 months post injection, overt metastases were not apparent. Splenocyte T cell populations were assessed by flow cytometry. CD3ε+ T cells were detected in tumor cell implanted mice but were not detected in WT splenocyte implanted mice (Figure 3G). Tumor-transplanted mice had measurable CD4+ T cells and substantial CD8+ T cells present (Figure 3H). Together, these data demonstrate that cells derived from tumors in Gzmb-HBZ mice were transplantable.

### Decreased bone volume and hypercalcemia in Gzmb-HBZ mice

ATL is associated with bone loss and hypercalcemia of malignancy; therefore, bone loss was evaluated in the Gzmb-HBZ mice. Initial X-ray comparison of tibiae suggested Gzmb-HBZ had reduced bone compared to WT mice at 18 months (Figure 4A). At 4 and 12 months of age, 2 parameters of bone loss, bone volume/tissue volume (BV/TV) and trabecular thickness (Tb.Th.), were similar between WT and Gzmb-HBZ mice by microCT analysis (Figure 4B and Supplementary Figure 2A, 2B). By 18 months, BV/TV was significantly reduced in Gzmb-HBZ mice (-66%) compared to WT mice (0.06 ± 0.01, 0.18 ± 0.03). Tb.Th was also reduced in Gzmb-HBZ mice (-30%).

---

**Figure 3: T cells from Gzmb-HBZ mice are transplantable.** A. Spleen weights from NSG mice implanted intravenously with PBS or mesenteric lymph node tumor cells (n = 5/group). B. Splenic CD4 and C. CD8 T cells from sham or tumor implanted mice. D. Image of a Gzmb-HBZ mouse 2-months post intraperitoneal tumor cell implantation with corresponding spleen weight E. and thymus weight F. *Red asterisk denotes a tumor. Percent of splenic CD3ε T cells G. or CD4 and CD8 H. T cells from NSG mice serially implanted with tumor cells (D) or WT splenocytes (n = 5/group). All data reported as mean +/- SEM with statistical significance determined by Mann-Whitney U-test A. or unpaired t-test B, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
compared to WT mice (0.07 ± 0.002 mm, 0.1 ± 0.003 mm) (Figure 4C, 4D). Osteoclasts (OC) are bone-resorbing cells frequently increased in number and function in ATL patients and patients with bone metastases. To determine if the OC number or OC surface/bone surface (OC.S/BS) was changed in Gzmb-HBZ mice, tartrate-resistant acid phosphatase (TRAP) stains of OC from histological sections of bone were evaluated. Osteoclast surface/bone surface (OC.S/BS) but not OC number (OC.N) was significantly increased in Gzmb-HBZ mice, suggesting enhanced bone resorption (Figure 4E, 4F and Supplementary Figure 2C). Some cancer cells modulate the bone microenvironment by altering the activity of bone forming osteoblasts. Procollagen Type I Intact N-terminal Propeptide (P1NP) is released during bone formation and can be used as a marker for osteoblast activity. WT and Gzmb-HBZ mice had similar levels of serum P1NP, indicating bone formation at 18 months is unchanged with HBZ expression (Figure 4G). Hypercalcemia due to resorption of bone is a serious complication for ATL patients. Serum calcium levels were significantly increased in Gzmb-HBZ mice (10.8 ± 0.53) compared to WT controls (8.62 ± 0.31) (Figure 4H). Thus, Gzmb-HBZ mice model the lymphoproliferative disease, bone loss and hypercalcemia present in HTLV-1 associated ATL.

**Figure 4: Gzmb-HBZ mice develop bone loss and hypercalcemia.** A. Representative X-ray images of WT and Gzmb-HBZ tibiae. MicroCT analysis of bone volume/tissue volume (BV/TV) and trabecular thickness (Tb.Th) at 4 months of age (n = 5/group) B. and 18 months of age C. in WT (n = 7) and Gzmb-HBZ (n = 13) mice. D. MicroCT representative images. Scale bar = 300 µm. TRAP+ cells (arrowheads) E. and quantification of osteoclast surface per bone surface F. in WT (n = 5) and Gzmb-HBZ (n = 3) tibiae. Scale bar = 50 µm. G. Enzyme-linked immunosorbent assay (ELISA) for osteoblast activity marker Procollagen Type I Intact N-terminal Propeptide (P1NP), measured in serum from Gzmb-HBZ (n = 4) and WT (n = 7) mice. H. Serum calcium levels in WT (n = 5) and Gzmb-HBZ (n = 4) mice at 18 months. All data reported as mean +/- SEM. Statistical significance was determined by unpaired t-test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
Figure 5: Gzmb-HBZ mice have systemic inflammation and increased T-cell derived bone-acting factors. A. ELISA quantification of serum cytokines in 18-month WT (n = 3) and Gzmb-HBZ (n = 3) mice. Flow cytometry analysis of ex vivo expanded T cell populations B. and IFNγ expression C. from WT and Gzmb-HBZ splenocytes. Granzyme B D., HBZ E., PTHrP F., RANKL G., and DKK1 H. mRNA expression in WT and Gzmb-HBZ ex vivo cultured, activated T cells. Data is representative of 2-3 biological replicates. All data reported as mean +/- SEM. Statistical significance determined by unpaired t-test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
Gzmb-HBZ mice have increased inflammatory and bone-acting cytokines in serum

Chronic inflammation and cancer can cause bone loss through multiple mechanisms. Tumors can secrete factors that act directly on bone resorbing osteoclasts (OC) or can have indirect effects on OCs through other cell types in the bone microenvironment. Serum from 18-month old, fasted Gzmb-HBZ (n = 3) and WT (n = 3) mice was analyzed for changes in cytokines and chemokines using a quantitative glass-slide antibody array. Inflammatory cytokines IFNγ and IL-6 were significantly increased in serum from Gzbmb-HBZ mice compared to WT mice (Figure 5A). Furthermore, multiple factors that have been shown to directly and indirectly affect bone were significantly increased in Gzmb-HBZ mice compared to WT mice, including IL-6, MCP-1, and IL-3. Several factors trended toward increased levels in serum of Gzmb-HBZ mice such as IL-17, RANTES and IL-1β but did not reach statistical significance. The concentration of IL-2 in serum was similar between Gzmb-HBZ and WT mice, demonstrating that cytokines upregulated in Gzmb-HBZ transgenic mice were enriched in inflammatory and bone-acting factors.

To determine whether T-cells from HBZ mice express inflammatory factors, splenocytes from WT and Gzmb-HBZ mice were isolated and activated in culture on CD3/CD28 coated tissue culture plates followed by expansion in IL-2 containing media. Similar to CD8 T cell expansion in Gzmb-HBZ tumor cell transplanted mice, CD8 T cells were substantially increased in Gzmb-HBZ ex vivo T cell cultures (Figure 5B). Further, CD8 but not CD4 T cells had enhanced IFNγ by flow cytometry analysis (Figure 5C), demonstrating increased serum inflammatory factors in Gzmb-HBZ mice may in part be due to enhanced T cell expression.

Parathyroid hormone related protein (PTHrP) is an important mediator of hypercalcemia and osteolytic bone loss through upregulation of RANKL whereas; the Dickkopf-WNT signaling pathway inhibitor 1 (DKK1) inhibits osteoblast bone formation, thus altering the bone resorption/bone formation balance of the bone microenvironment towards osteolytic bone loss. To evaluate the effects of HBZ expression in T cells on expression of these bone modifying proteins, splenocytes from WT and Gzmb-HBZ mice were isolated and expanded in culture on CD3/CD28 coated tissue culture plates for 24hrs. Granzyme B and HBZ expression were expanded in culture on CD3/CD28 coated tissue culture plates for 24hrs. Granzyme B and HBZ expression were expanded in culture. Granzyme B Tax mice [5]. This may in part be attributed to the previously reported weaker oncogenic potential of HBZ compared to Tax. Indeed, HBZ mice develop the peripheral subcutaneous tumors characteristic of Gzmb-HBZ mice. Further, CD4-HBZ mice were characteristic of the Gzmb-HBZ mice, but were not reported in the CD4-HBZ mice. Further, CD4-HBZ mice developed dermatitis not present in the Gzmb-HBZ model. We also observed HBZ expression in CD4 T cells from Gzmb-HBZ mice. In contrast, enlarged lymph node tumors were characteristic of the Gzmb-HBZ mice, but were not reported in the CD4-HBZ mice. Further, CD4-HBZ mice developed dermatitis not present in the Gzmb-HBZ model. The different expression patterns between CD4 (CD4 T helper cells) and Granzyme B (mature cytotoxic T and NK cells) promoters may explain some of the phenotypic differences seen in these models.

Interestingly, independent expression of HTLV-1 oncogenes Tax and HBZ by the same promoter, Granzyme B, resulted in very different tumor phenotypes in transgenic mice. Although both developed tumors in lymphatic tissues, Gzmb-HBZ mice did not develop the peripheral subcutaneous tumors characteristic of Gzmb-HBZ Tax mice [5]. This may in part be attributed to the previously reported weaker oncogenic potential of HBZ compared to Tax. Indeed, HBZ mice develop lymphoproliferative disease after an 18-month latency as

DISCUSSION

HTLV-1 induced ATL is associated with significant skeletal complications including hypercalcemia and osteolytic bone lesions. The HTLV-1 viral oncogene, Tax, regulates the expression of osteoclast-acting factors and may be a primary driver of bone pathology in ATL. We show for the first time, that HBZ transgenic mice also develop pathologic bone loss in addition to lymphoproliferative disease, suggesting that HBZ may also play a causative role in the pathogenesis of ATL induced bone loss. HBZ is a particularly compelling candidate for pathologic bone loss in ATL because Tax expression is frequently repressed in ATL cells, particularly at later stages, while HBZ is ubiquitously expressed in ATL cells and in all ATL disease stages [14]. We evaluated 4, 12 and 18-month cohorts of Granzyme B HBZ (Gzmb-HBZ) mice for tumor formation and bone loss. Tumors and hematopoietic changes were not evident until the 18-month time point. Interestingly, there is also a long latency between HTLV-1 infection and the development of ATL. We found that two-thirds of Gzmb-HBZ mice developed lymphoproliferative disease including palpable tumors, enlarged lymph and/or abnormal white blood cell counts. Overt tumors were present primarily in lymphoid and mesenteric tissues and were composed of significant numbers of CD45+ hematopoietic cells including CD3ε+ T cells that encompass both CD4 and CD8 T cells.

We observed several key similarities between our Gzmb-HBZ mice and recently published CD4-HBZ transgenic mice [21]. The CD4-HBZ mice develop leukemia at older ages, around 16 months, with changes in hematopoietic profiles, splenic infiltration and systemic inflammation, as was observed in the Gzmb-HBZ mice. We also observed HBZ expression in CD4 T cells from Gzmb-HBZ mice. In contrast, enlarged lymph node tumors were characteristic of the Gzmb-HBZ mice, but were not reported in the CD4-HBZ mice. Further, CD4-HBZ mice developed dermatitis not present in the Gzmb-HBZ model. The different expression patterns between CD4 (CD4 T helper cells) and Granzyme B (mature cytotoxic T and NK cells) promoters may explain some of the phenotypic differences seen in these models.
compared to the 6-9 month latency to malignancy in the Granzyme B Tax mice, further supporting that Tax is a more potent oncogene.

Characterization of malignant cells within tumors was more challenging than anticipated. NSG mice transplanted with cells from a primary Gzmb-HBZ tumor had detectable CD4 and CD8 T cells in the spleen. NSG mice implanted with serially passaged tumor cells, had measurable CD4 T cells present and substantial expansion of CD8+ T cells, suggesting lymphoproliferative disease was transplantable, a hallmark of malignant transformation. Importantly, Granzyme B is highly expressed in CD8 T cells and is expressed in some cytotoxic CD4 subsets. Recent studies have found that in HTLV-1 infected patients, infected CD8+ T cell undergo greater oligoclonal proliferation than infected CD4+ cells; however; CD8+ ATL is rare suggesting that clonal T-cell proliferation does not predispose patients to malignant disease [30]. In the CD4-HBZ transgenic mouse model, an ATL stem cell candidate (c-kit+/CD4+/CD8-) was identified and the c-kit-SCF signaling pathway was implicated in leukemia development. It would be interesting to determine if this population is present in the serially transplanted Gzmb-HBZ lymphoproliferative cell population [31].

Cells within Gzmb-HBZ tumors expressed HBZ protein and RNA. HBZ positive cells comprised a small number of total cells, making characterization of the malignant cells within tumors more difficult. It is possible that HBZ expression was lost in tumors, perhaps through promoter methylation [32]. Experiments using inducible systems could address the necessity of persistent HBZ expression and tumor formation. Another possibility is that low HBZ expression in the tumor could indicate that HBZ is indirectly effecting tumor formation through inflammation or other signaling pathways. Inflammation has been reported to increase tumor formation and loss of IL-15 promoted tumor development in the Granzyme B Tax model [33]. Importantly, the CD4-HBZ transgenic model also reported systemic inflammation that contributed to leukemia onset [21, 34]. We similarly found that the Gzmb-HBZ transgenic mice had inflammatory cytokines in the serum and in ex vivo T cell cultures. Thus, it is possible that indirect HBZ-mediated effects caused tumors in Gzmb-HBZ mice. Future studies will interrogate the role of HBZ and HBZ-associated factors in malignant transformation and tumor formation in transplantation studies. In addition, it has recently been reported that HBZ protein and RNA have distinct functions in T-cell proliferation and survival. HBZ protein has been shown to regulate transcription of immune-associated genes while RNA was associated with genes related to cell proliferation. It will be important to delineate the differential effects of RNA and protein on oncogenesis and bone loss in HTLV-1 associated ATL [15, 35].

In Gzmb-HBZ transgenic mice, development of bone loss and hypercalcemia coincided with lymphoproliferative disease, demonstrating HBZ-mediated bone loss in vivo for the first time. Bone is continuously remodeled and the process of bone resorption (osteoclasts) and bone formation (osteoblasts) is tightly coupled. Some diseases including cancer disrupt this coupling causing a net increase (prostate cancer) or decrease (breast cancer) of bone. Although osteoclast number was unchanged in Gzmb-HBZ and WT mice, osteoclast size was increased in Gzmb-HBZ mice. OC size is measured by length on the bone surface and a larger size can represent an increase in resorptive surface and accelerated bone loss. Osteoblast activity measured by serum collagen marker P1NP, was similar between Gzmb-HBZ and WT. It has been reported that by 18 months, there is little bone formation and this may explain why there was no difference in the osteoblast activity marker P1NP between WT and Gzmb-HBZ mice. Of note, Gzmb-HBZ tibiae did not have osteolytic lesions characteristic of a localized tumor effect but instead had an overall thinning of the trabeculae representative of systemic bone loss seen in some types of cancer, including breast cancer. We have previously shown that Tax transgenic mice (under the Granzyme B promoter) develop bone loss and hypercalcemia by 9 months of age. We now demonstrate that HBZ expression can have significant effects on bone loss, independent of Tax or other viral pathogenesis factors.

Since significant lymphoproliferative disease was not present in the bone marrow of Gzmb-HBZ mice and cells that express HBZ were detectable in bone marrow in only limited numbers, we assessed expression of bone-acting and pro-inflammatory factors in serum. Cytokines have important effects on bone resorptive osteoclasts and can induce systemic bone loss [25]. We found that factors known to promote bone loss in solid and hematologic cancers (IL-6, MCP-1 and IL-3) were significantly elevated serum from Gzmb-HBZ mice compared to WT mice, indicating HBZ-mediated changes in cytokine secretion may directly or indirectly accelerate bone loss in this model. In addition, chronic inflammation causes osteolytic bone loss in diseases such as rheumatoid arthritis. Gzmb-HBZ mice had elevated levels of serum inflammatory cytokines and inflammation could contribute to bone loss in this model.

Several factors including, IL-1, MIP1α, RANKL and PTHrP, have been implicated in ATL mediated hypercalcemia and bone loss. Parathyroid hormone-related protein (PTHrP) induces hypercalcemia and systemic bone loss, in part, through upregulation of RANKL, a critical factor in osteoclast formation, and enhanced bone resorption. PTHrP expression is increased in HTLV-1 infected cell lines, patient serum and in primary ATL cells, however little is known about the regulation of PTHrP expression by the HTLV-1 virus [23]. We found that in addition to Granzyme B and HBZ, PTHrP was significantly increased in T cells isolated from Gzmb-
HBZ mice, providing the first in vivo evidence that HBZ could mediate hypercalcemia through enhanced PTHrP expression. Receptor activator of nuclear factor kappa-B ligand (RANKL) expression by some tumor types increases osteoclast formation and promotes bone resorption. Overexpression of the RANKL gene in ATL patients correlates with hypercalcemia [36]. In our transgenic mouse model, RANKL expression was significantly increased compared to WT mice, supporting a potential role for RANKL in HTLV-1 mediated bone loss. In addition, expression of the WNT pathway inhibitor Dickkopf-1 (DKK1) was increased by HBZ expression in vitro [29]. DKK1 inhibits bone-forming osteoblasts to promote bone loss in metastatic and hematopoietic malignancies [37]. We found that DKK1 expression was also increased in Gzmb-HBZ T cells compared to WT controls in vivo, suggesting HBZ may directly or indirectly effect DKK1 expression. Thus, in the Gzmb-HBZ mouse model, expression of PTHrP, RANKL and DKK1, known inducers of hypercalcemia and bone loss and therapeutic targets for osteoporosis and cancer, were increased in T cells.

In this work, we have shown that Gzmb-HBZ mice developed lymphoproliferative disease and model the bone loss and hypercalcemia present in ATL patients. We further identified elevated bone-acting factors in both serum and T cells from Gzmb-HBZ mice. Importantly, these factors have established roles in pathologic bone loss in osteoporosis, metastatic cancer and chronic inflammatory diseases. We thus demonstrated for the first time in an animal model, that the HTLV-1 oncogene HBZ might have an important role in ATL-mediated bone loss independent of Tax and suggest that HBZ-mediated bone loss may respond to current therapies for bone resident and metastatic tumors. Additional studies are needed to evaluate the effects of HBZ on bone loss in the context of the entire HTLV-1 genome.

MATERIALS AND METHODS

Animal studies

An independent transgenic Gzmb-HBZ mouse colony was derived and bred in the Weilbaecher lab from TAX-Luciferase-HBZ transgenic mice (C57Bl/6j; FVB), a generous gift from Dr. Lee Ratner. In the TAX-Luc-HBZ model (unpublished), the Granzyme B promoter regulates TAX and HBZ expression. The 5’LTR fragment of pHTE-1 regulates firefly luciferase (pGL-3; Promega). Individual Granzyme B TAX [5] and Granzyme B TAX-Luc [38] strains have been previously described. For evaluation, 4, 12 and 18-month cohorts of WT (n = 8), and Gzmb-HBZ mice (n = 8) were generated. A second cohort of 18-month Gzmb-HBZ mice was generated to facilitate evaluation of tumor heterogeneity (n = 7). Cohorts consisted of equal numbers of male and female mice. Animals were housed under pathogen-free conditions according to the guidelines of the Division of Comparative Medicine, Washington University (St. Louis, MO). Animal studies were performed under protocols approved and monitored by the Washington University Institutional Animal Care and Use Committee.

Construction of the HBZ transgene

The Granzyme B promoter flanked by EcoRV sites (using DRGZBL and DRGZBR primers shown) was inserted into the Snal linearized pHBZ1 plasmid [39]. The purified 2.7kb transgene (produced using DRGZBL and DRGZBHBZR primers) was used for microinjections. Primers; DRGZBL: GGATATCGAATTCTATATTTTGAG, DRGZBR: ACGCGATATCCTGTGTTTTTCCTCCTT and DRGZBHBZR: TTCCACAGCCAAGCTGGCCG.

Quantitative RT-PCR

RNA was extracted from either cells or frozen tissue homogenized by mortar and pestle using the RNeasy Mini kit (Qiagen, Venlo, Netherlands) and cDNA generated with iScript (Bio-Rad, Hercules, CA, USA). Quantitative PCR was completed using SsoFast EVA Green Supermix (Bio-Rad). For HBZ expression, RNA was treated with DNase (Invitrogen) prior to RT-PCR. All steps were completed following the manufacturers instructions. Granzyme B (Forward-CCACTCTCGACCTCATAGGG; Reverse-GGCCCAAGTGACATTATT), Cyclophilin A (Forward-AGCATACAGTCCTGGCATC; Reverse- TTCACCTCTCCCAAAGACCAC), PTHrP (Forward-CTACAGTCATGCAAGGCAG; Reverse-GGTGTTTTTGTGTTGGGAG), DKK1 (Forward-CTCCAGAAGACCAACACTGA, Reverse- GTCTGATGATCGGAGGAG).

Histology and immunohistochemistry

Tissues were fixed in 10% formalin for paraffin embedding. Tibias were decalcified in 14% EDTA prior to paraffin embedding. 5µm sections were stained by immunohistochemistry (IHC) with rat anti-mouse CD45 (BD Pharmingen #550539), CD3 (Dako #A0452), B220 (BD Pharmingen #550286). Flag-tagged HBZ expression was detected following citrate antigen retrieval with the anti-flag antibody (Sigma #F1804, 5ug/ml) and detected using the Histomouse-Plus Broad Spectrum (AEC) kit (Life Technologies, catalog #849541). Tibias were stained with the tartrate-resistant acid phosphatase (TRAP) (Sigma-Aldrich) to visualize osteoclasts. The number
and surface area of TRAP+ cells/bone surface area were quantified at 5X magnification for WT (n = 7) and HBZ (n = 7) mice. Images were acquired using the NanoZoomer 2.0-HT System (Hamamatsu Photonics) or the Zeiss Axio Scan Z1.

**RNA in situ hybridization**

Paraffin embedded tissue was stained for RNA via *in situ* hybridization (RNAscope Manual Assay 2.5HD-BROWN kit, ADC Biotechnology). Tissues were deparaffinized and pretreated with hydrogen peroxide, protease, and an antigen retrieval solution as directed. Antigen retrieval was performed in a pressure cooker for 30 minutes followed by incubation with the HBZ probe or the provided negative and positive controls. The HBZ probe (ADC Biotechnology) has a target region from 173-1363 in the HBZ RNA. The negative control probe hybridized the E. Coli gene *DapB* and the positive control probe hybridized the mouse housekeeping gene *Ppib*, Tissue sections were stained with DAB and hematoxylin, and mounted (Clearmount medium). Images were scanned using the Nanozoomer digital slide scanner (Hamamatsu Photonics). Five images at 60X magnification were taken randomly for each sample and positive cells/total cell number was quantified manually.

**Tumor implantation**

Cells were isolated from a spontaneous mesenteric Gzmb-HBZ tumor by mechanical disruption through a 70um cell strainer and frozen in 7% DMSO containing media and stored in liquid nitrogen. NSG or Gzmb-HBZ mice were implanted by intravenous or intraperitoneal injection of 1x10^7 tumor cells following twice PBS washes. In the Gzmb-HBZ mice, the secondary tumor was isolated mechanically as described and frozen and stored in liquid nitrogen. Thawed cells were washed twice in PBS and i.v. implanted in NSG mice at 1x10^7 cells per mouse.

**Flow cytometry**

Spleens were mechanically disrupted through a 70µm cell strainer. Cells were washed with PBS and red blood cells lysed (Sigma-Aldrich, #R7757). Cells were washed twice, centrifuged and blocked for 10 minutes on ice. Cells were resuspended in antibody diluent containing fluorophore-conjugated antibodies at 1:200 (ebioscience antibodies CD45, CD3ε, CD4 and CD8). Cells were incubated 1 hour on ice, then washed twice in PBS and resuspended in FACS buffer (5% FBS in PBS) for analysis on the BD Bioscience LSRFortessa.

**MicroCT of WT and Gzmb-HBZ tibiae**

Tibiae were scanned by micro-computed tomography (μCT) (μCT-40; Scanco Medical). The trabecular region from forty 2D slices (0.8 mm) was selected using contours inside the cortical shell on each 2D image, with the growth plate as a marker to determine a consistent location to start analysis. A 3D cubical voxel model of bone was built, and calculations were made for bone volume/tissue volume (BV/TV) and trabecular thickness (Tb.Th) and bone mineral density (BMD) calibrated against a hydroxyapatite phantom. A threshold of 300 (out of 1,000) was used to differentiate trabecular bone from non-bone.

**Mouse cytokine serum array**

Serum was collected from WT (n = 3) and Gzmb-HBZ (n = 3) mice after 16 hours without food and was frozen at -80 degrees Celsius. Thawed serum was applied to a glass slide antibody array and processed according to manufacturer’s instructions (QAM-CYT-1-1, Raybiotech). Raybiotech completed slide scanning and data extraction. The primary author analyzed raw data. For analysis, background was subtracted and mean values were determined (3-4 replicates per cytokine) and converted from fluorescence unit to protein concentration by a standard curve best-fit regression specific for each cytokine.

**Ex vivo T cell culture**

Spleens were gently mechanically disassociated through a 70um cell strainer. Isolated cells were plated in a tissue culture treated plate overnight at 37 degrees Celsius in media (RPMI, 5% FBS). Non-adherent cells were transferred to CD3ε/CD28 coated 6-well plates in T cell media (RPMI, 5% FBS, 1% P/S, IL-2) for 24hrs at 37 degrees Celsius. Cells were collected, rinsed in PBS and RNA isolated by RNeasy RNA isolation kit (Qiagen). Remaining cells were plated in 6-well tissue culture plates with T cell media, expanded for 3 days and analyzed by flow cytometry as described above.

**Statistics**

Data are shown as mean with error bars representing standard error of the mean (mean ± SEM), unless otherwise specified. Differences among experimental groups were analyzed using a two-tailed *t*-test or Fisher’s exact test (tumor incidence and WBC counts) as appropriate. Assumptions for *t*-test analyses (independent samples, approximately normal distributions) for samples
n > 5 were sufficiently met, or satisfied if a random sample of n ≤ 5 were selected from an approximately normally distributed population. For data where the sample number was too small to determine normality (n ≤ 5 independent samples or biological replicates), but where the variance between groups was similar (using the F-test for equality of variances), two-tailed t-test analyses [40] were used where appropriate. For non-normally distributed data, differences among experimental groups were analyzed using a two-tailed Mann-Whitney U-test for unpaired samples. All tests were considered significant at P ≤ 0.05. Data analyses were complete using Prism 6 (GraphPad Software).

Abbreviations

Human T cell leukemia/lymphoma virus (HTLV-1); Adult T cell leukemia/lymphoma (ATL); Granzyme B HBZ (Gzmb-HBZ); Osteoclasts (OC); Trabecular thickness (Tb.Th); Bone volume/ tissue volume (BV/TV); Osteoclast surface/ bone surface (OC.S/BS); Tartrate-resistant acid phosphatase (TRAP).

Author contributions

Conception and design: A. Esser, D. Rauch, L. Ratner, K.N. Weilbaecher
Development of methodology: A. Esser, M. Ross, J. Xiang, K.N. Weilbaecher. K. Wu, J. Harding, P. Green, D. Rauch, L. Ratner, K.N. Weilbaecher.
Acquisition of data: A. Esser, J. Xiang, J. Harding, N. Kohart, M. Ross, X. Su, K. Wu, D. Huey, Y. Su, T. Rosol, S. Niewiesk, L. Ratner, K.N. Weilbaecher.
Analysis and interpretation of data: A. Esser, J. Xiang, M. Ross, S. Xu, N. Kohart, K. Vij, T. Rosol, D. Rauch, L. Ratner, K.N. Weilbaecher.
Writing, review, and/or revision of the manuscript: A. Esser, J. Xiang, M. Ross, D. Rauch, L. Ratner, T. Rosol, S. Niewiesk, P. Green, K.N. Weilbaecher.

ACKNOWLEDGMENTS

The authors thank Dr. Francesca Fontana and Gregg Fox for their valuable suggestions and criticism and Crystal Idleburg and Amanda Panfil for their expert technical assistance. The authors thank Gunjan Choudhary for providing the pHBZ1 plasmid and confirming HBZ-FLAG expression from the transgene. The authors also thank the Musculoskeletal Research Center for histology and microCT (NIH P30-AR057235), the Hope Center Alafi Neuroimaging Lab for use of the Nanozoomer (NIH shared Instrumentation grant #S10RR027552), and the Washington University Center for Cellular Imaging (WUCI) supported by the Washington University School of Medicine for use of the Zeiss Axio Scan Z1 Brightfield/Fluorescence Slide Scanner and the St. Louis Men’s Group against Cancer.

CONFLICTS OF INTEREST

None.

FUNDING

K. Weilbaecher, A. Esser, J. Xiang were supported by the NIH program project grant 5P01CA100730-10 and R01-CA154737. M.H. Ross was supported by NIH grants 5T32GM007067 and T32AR060719. A.K. Esser was supported by NIH grants 5T32CA113275-07 and 5F32CA189671-02. N. Kohart was supported by the NIH grant T32OD010429.

REFERENCES

1. Bangham CR, Ratner L. How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)? Curr Opin Virol. 2015; 14:93-100. doi: 10.1016/j.coviro.2015.09.004.
2. Watanabe T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood. 2017; 129:1071-81. doi: 10.1182/blood-2016-09-692574.
3. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991; 79:428-37.
4. Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike N, Yoshiida S, Yamashita K, Tsukasaki K, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015; 126:2570-7. doi: 10.1182/blood-2015-03-632489.
5. Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A. 1995; 92:1057-61.
6. Hasegawa H, Sawa H, Lewis MJ, Orba Y, Sheehy N, Yamamoto Y, Ichinohe T, Tsunetsugu-Yokota Y, Kato H, Takahashi H, Matsuda J, Sata T, Kurata T, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med. 2006; 12; 466-72. doi: 10.1038/nm1389.
7. Szerlong HJ, Prenni JE, Nyborg JK, Hansen JC. Activator-dependent p300 acetylation of chromatin in vitro: enhancement of transcription by disruption of repressive nucleosome-nucleosome interactions. J Biol Chem. 2010; 285; 31954-64. doi: 10.1074/jbc.M110.148718.
8. Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 2011; 30:1379-89. doi: 10.1038/onc.2010.537.
9. Choi YB, Harhaj EW. HTLV-1 tax stabilizes MCL-1 via TRAF6-dependent K63-linked polyubiquitination to promote cell survival and transformation. PLoS Pathog. 2014; 10:e1004458. doi: 10.1371/journal.ppat.1004458.

10. Baydoun HH, Bai XT, Shelton S, Nicot C. HTLV-I tax increases genetic instability by inducing DNA double strand breaks during DNA replication and switching repair to NHEJ. PLoS One. 2012; 7:e42226. doi: 10.1371/journal.pone.0042226.

11. Chevalier SA, Turpin J, Cachat A, Afonso PV, Guessain A, Brady JN, Pise-Masison CA, Mahieux R. Gem-induced cytoskeleton remodeling increases cellular migration of HTLV-1-infected cells, formation of infected-to-target T-cell conjugates and viral transmission. PLoS Pathog. 2014; 10:e1003917. doi: 10.1371/journal.ppat.1003917.

12. Kinoshita T, Shiomiyama M, Tobinai K, Ito M, Ito S, Ikeda S, Tajima K, Shimotohno K, Sugimura T. Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989; 86:5620-4.

13. Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J, Nosaka K, Tanaka Y, Matsuoka M. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer. 2004; 109:559-67. doi: 10.1002/ijc.20007.

14. Miyazaki M, Yasunaga J, Taniguchi Y, Tamiya S, Nakahata T, Matsuoka M. Preferential selection of human T-cell leukemia virus type 1 provirus lacking the 5′ long terminal repeat during oncogenesis. J Virol. 2007; 81:5714-23. doi: 10.1128/JVI.02511-06.

15. Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T-cell leukemia cells. Proc Natl Acad Sci U S A. 2006; 103:720-5. doi: 10.1073/pnas.0507631103.

16. Thebaud S, Babsbous H, Hivin P, Devaux C, Mesnard JM. HBZ interacts with JunD and stimulates its transcriptional activity. FEBS Lett. 2004; 562:165-70. doi: 10.1016/S0014-5793(04)00225-X.

17. Zhao T, Yasunaga J, Satou Y, Nakao M, Takahashi M, Fujii M, Matsuoka M. Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood. 2009; 113:2755-64. doi: 10.1182/blood-2008-06-161729.

18. Arnold J, Zimmerman B, Li M, Lairmore MD, Green PL. Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation. Blood. 2008; 112:3788-97. doi: 10.1182/blood-2008-04-154286.

19. Wright DG, Marchal C, Hoang K, Ankeny JA, Nguyen ST, Rushing AW, Polakowski N, Miotto B, Lemasson I. Human T-cell leukemia virus type-1-encoded protein HBZ represses p53 function by inhibiting the acetyltransferase activity of p300/CBP and HBO1. Oncotarget. 2016; 7:1687-706. doi: 10.18632/oncotarget.6424.

20. Gazon H, Belrose G, Terol M, Meniane JC, Mesnard JM, Césaire R, Peloponese JM Jr. Impaired expression of DICER and some microRNAs in HBZ expressing cells from acute adult T-cell leukemia patients. Oncotarget. 2016; 7:30258-75. doi: 10.18632/oncotarget.7162.

21. Satou Y, Yasunaga J, Zhao T, Yoshida M, Miyazato P, Takai K, Shimizu K, Ohshima K, Green PL, Ohkura N, Yamaguchi T, Ono M, Sakaguchi S, et al. HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog. 2011; 7:e1001274. doi: 10.1371/journal.ppat.1001274.

22. Yamamoto-Taguchi N, Satou Y, Miyazato P, Ohshima K, Nakagawa M, Katagiri K, Kinashi T, Matsuoka M. HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression. PLoS Pathog. 2013; 9:e1003630. doi: 10.1371/journal.ppat.1003630.

23. Shu ST, Martin CK, Thudi NK, Dirksen WP, Rosol TJ. Osteolytic bone resorption in adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2010; 51:702-14. doi: 10.3109/10428191003646697.

24. Elshafae SM, Kohart NA, Altstadt LA, Dirksen WP, Rosol TJ. The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis. Prostate. 2017; 77:776-93. doi: 10.1002/pros.23318.

25. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011; 11:411-25. doi: 10.1038/nrc3055.

26. Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Pwnica-Worms D, Rogers MJ, Weilbaecher K. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone. 2009; 44:908-16. doi: 10.1016/j.bone.2009.01.010.

27. Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, Weilbaecher K. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood. 2005; 106:4294-302. doi: 10.1182/blood-2005-04-1730.

28. Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs ST, Rushing AW, Polakowski N, Miotto B, Lemasson I, Piwnica-Worms D, Rogers MJ, Weilbaecher K. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone. 2009; 44:908-16. doi: 10.1016/j.bone.2009.01.010.

29. Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, Weilbaecher K. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood. 2005; 106:4294-302. doi: 10.1182/blood-2005-04-1730.

30. Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs ST, Rushing AW, Polakowski N, Miotto B, Lemasson I, Piwnica-Worms D, Rogers MJ, Weilbaecher K. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone. 2009; 44:908-16. doi: 10.1016/j.bone.2009.01.010.
expansion of infected CD8(+) T cells in natural infection. Retrovirology. 2015; 12:91. doi: 10.1186/s12977-015-0221-1.

31. Kuribayashi W, Takizawa K, Sugata K, Kuramitsu M, Momose H, Sasaki E, Hiradate Y, Furuhata K, Asada Y, Iwama A, Matsuoka M, Mizukami T, Hamaguchi I. Impact of the SCF signaling pathway on leukemia stem cell-mediated ATL initiation and progression in an HBZ transgenic mouse model. Oncotarget. 2016; 7:51027-43. doi: 10.18632/oncotarget.10210.

32. Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, Totoki Y, Chiba K, Sato-Otsubo A, Nagae G, Ishii R, Muto S, Kotani S, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015; 47:1304-15. doi: 10.1038/ng.3415.

33. Rauch DA, Harding JC, Ratner L. IL-15 deficient tax mice reveal a role for IL-1alpha in tumor immunity. PLoS One. 2014; 9:e85028. doi: 10.1371/journal.pone.0085028.

34. Mitagami Y, Yasunaga J, Kinosada H, Ohshima K, Matsuoka M. Interferon-gamma Promotes Inflammation and Development of T-Cell Lymphoma in HTLV-1 bZIP Factor Transgenic Mice. PLoS Pathog. 2015; 11:e1005120. doi: 10.1371/journal.ppat.1005120.

35. Mitobe Y, Yasunaga J, Furuta R, Matsuoka M. HTLV-1 bZIP Factor RNA and Protein Impart Distinct Functions on T-cell Proliferation and Survival. Cancer Res. 2015; 75:4143-52. doi: 10.1158/0008-5472.CAN-15-0942.

36. Nosaka K, Miyamoto T, Sakai T, Mitsuha H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood. 2002; 99:634-40.

37. Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer. 1997; 80:1557-63.

38. Rauch D, Gross S, Harding J, Niewiesk S, Lairmore M, Piwnica-Worms D, Ratner L. Imaging spontaneous tumorigenesis: inflammation precedes development of peripheral NK tumors. Blood. 2009; 113:1493-500. doi: 10.1182/blood-2008-07-166462.

39. Choudhary G, Ratner L. The HTLV-1 hbz antisense gene indirectly promotes tax expression via down-regulation of p30(II) mRNA. Virology. 2011; 410:307-15. doi: 10.1016/j.virol.2010.11.019.

40. de Winter J. Using the Student’s t-test with extremely small sample sizes. Practical Assessment, Research & Evaluation. 2013; 18:12.